Psychiatry/Behavioral · PANCE / PANRE

Schizophrenia

Written & clinically reviewed by Ryan Busch, PA-C · Updated August 2026 · Report an error

Chronic psychotic disorder with positive, negative, and cognitive symptoms persisting >=6 months.

Also known as: schizophrenia, psychotic disorder, primary psychosis

Overview

A chronic primary psychotic disorder defined by >=1 month of active-phase symptoms (>=2 of delusions, hallucinations, disorganized speech, grossly disorganized/catatonic behavior, negative symptoms — including at least one of the first three) with total disturbance >=6 months including prodromal/residual phases, and significant functional decline.

Epidemiology

Lifetime prevalence ~0.7-1%. Onset typically late teens to mid-20s in males, slightly later in females. Slight male predominance with earlier onset and worse outcomes.

Try two board-style Schizophrenia questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1PsychiatryMedium
A 35-year-old female with schizophrenia has been stable on haloperidol for 2 years but developed tardive dyskinesia. Her psychiatrist wants to switch to an antipsychotic with the lowest tardive dyskinesia risk that is also effective for treatment-resistant schizophrenia. Which of the following agents is most appropriate?
  • AClozapine
  • BAripiprazole
  • CQuetiapine
  • DOlanzapine
Reveal answer & full explanation
Correct answer: A — Clozapine
  • AClozapine✓
  • BAripiprazole
  • CQuetiapine
  • DOlanzapine

Why Clozapine is correct

  • Clozapine has the lowest risk of extrapyramidal symptoms (EPS) and tardive dyskinesia of all antipsychotics.
  • Mechanism: weak D2 blockade (only 60-65%) with strong 5-HT2A antagonism plus H1, M1, and alpha-1 antagonism — accounts for low EPS risk.
  • It is the only antipsychotic FDA-approved for: (1) treatment-resistant schizophrenia (TRS — defined as failure of 2 adequate antipsychotic trials); and (2) reducing suicidal behavior in schizophrenia/schizoaffective disorder.

Why the others are wrong

  • Aripiprazole — a partial D2 agonist with low EPS risk, but not approved for treatment-resistant schizophrenia and lacks the clozapine evidence base for TRS (right-concept-wrong-drug).
  • Quetiapine — relatively low EPS risk, but not indicated for treatment-resistant schizophrenia (anchoring on low EPS alone).
  • Olanzapine — effective second-generation antipsychotic but carries significant metabolic side effects and is not preferred for TRS (premature closure).

Additional high-yield points

  • Agranulocytosis occurs in approximately 1% of patients on clozapine, requiring mandatory Risk Evaluation and Mitigation Strategy (REMS) monitoring: weekly complete blood count (CBC) for 6 months, biweekly CBC for 6 months, then monthly if stable.
  • Other clozapine side effects: weight gain, metabolic syndrome, myocarditis (early — monitor C-reactive protein (CRP) and troponin), seizures (dose-dependent), excessive salivation, constipation, orthostatic hypotension.
  • Vesicular monoamine transporter 2 (VMAT2) inhibitors (valbenazine, deutetrabenazine) treat established tardive dyskinesia (TD) in patients who remain on the offending antipsychotic.
Question 2PsychiatryMedium
A 35-year-old male with schizophrenia on olanzapine 20 mg daily for 3 years has gained 35 lbs and now has type 2 diabetes (HbA1c 8.2%). His psychosis is well controlled. Which of the following antipsychotics is most appropriate to switch to in order to reduce metabolic risk?
  • AAripiprazole
  • BRisperidone
  • CQuetiapine
  • DClozapine
Reveal answer & full explanation
Correct answer: A — Aripiprazole
  • AAripiprazole✓
  • BRisperidone
  • CQuetiapine
  • DClozapine

Why Aripiprazole is correct

  • Olanzapine and clozapine carry the highest metabolic burden among antipsychotics (weight gain, type 2 diabetes, dyslipidemia), and this patient has already developed olanzapine-attributable obesity and T2DM with well-controlled psychosis
  • Aripiprazole, a partial dopamine agonist, has among the lowest metabolic liability of the second-generation agents (along with ziprasidone and lurasidone), making it the preferred switch target to reduce weight and glycemic risk
  • Per APA/ADA consensus, when antipsychotic-induced metabolic complications develop, switching to a lower-risk agent via gradual cross-taper over 4-6 weeks with relapse monitoring is recommended
  • The switch should be paired with shared decision-making, lifestyle intervention, and consideration of metformin (best adjunctive evidence for antipsychotic-associated weight gain) rather than presented as risk-free

Why the others are wrong

  • Risperidone — intermediate metabolic risk; an improvement over olanzapine but not the lowest-risk option, so it is not the best choice here (right-direction-wrong-degree)
  • Quetiapine — higher metabolic liability than aripiprazole and a poor target in a patient who already has T2DM from olanzapine (confused-with low-risk agent)
  • Clozapine — carries the highest metabolic risk alongside olanzapine and is reserved for treatment-resistant schizophrenia, so it worsens rather than reduces the problem (right-concept-wrong-drug)

Additional high-yield points

  • Adjuncts for antipsychotic-induced weight gain: metformin (best evidence), structured lifestyle intervention, and GLP-1 receptor agonists (emerging evidence)
  • APA/ADA monitoring: weight/BMI monthly x3 then quarterly; fasting glucose and lipids at baseline, 3 months, then annually
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Schizophrenia outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in
Free to start · No credit card · Cancel anytime

Risk factors

  • Family history (first-degree relative ~10% risk; monozygotic twin ~50%)
  • Advanced paternal age at conception
  • Obstetric complications, perinatal hypoxia, maternal infection (influenza in second trimester)
  • Urban upbringing, migration
  • Cannabis use in adolescence (especially high-potency THC)
  • Childhood adversity

Pathophysiology

Polygenic disorder with disruption of cortical development and synaptic pruning. Dopaminergic hyperactivity in mesolimbic pathways (positive symptoms) and hypoactivity in mesocortical pathways (negative/cognitive symptoms). NMDA receptor hypofunction, GABAergic interneuron deficits, neuroinflammation. Ventriculomegaly and reduced gray matter volume on imaging.

Clinical presentation

Symptoms

  • Positive: delusions (often persecutory or referential), hallucinations (auditory most common), disorganized speech (derailment, tangentiality, word salad), grossly disorganized/catatonic behavior
  • Negative: avolition, alogia, anhedonia, asociality, blunted/flat affect
  • Cognitive: deficits in attention, working memory, executive function, processing speed
  • Prodromal phase: social withdrawal, declining function, attenuated psychotic symptoms preceding overt psychosis by months to years

Signs / physical exam

  • Flat affect, poor eye contact, internal preoccupation
  • Thought disorder evident in speech
  • Catatonia: stupor, mutism, posturing, waxy flexibility, echolalia, echopraxia (now its own DSM specifier)
  • Neurological soft signs

Differential diagnosis

  • Schizophreniform disorder — Same symptoms 1-6 months without the social/occupational decline requirement
  • Brief psychotic disorder — Symptoms 1 day to 1 month with return to premorbid function
  • Schizoaffective disorder — Mood episode concurrent with psychosis, plus >=2 weeks of psychosis without mood symptoms
  • Bipolar I with psychotic features — Psychosis confined to mood episodes
  • MDD with psychotic features — Mood-congruent psychosis during depressive episode only
  • Substance/medication-induced psychosis — Stimulants, cannabis, hallucinogens, corticosteroids, anticholinergics; resolves with abstinence
  • Psychosis due to medical condition — Delirium, autoimmune encephalitis (anti-NMDA), temporal lobe epilepsy, Huntington, B12 deficiency, neurosyphilis
  • Delusional disorder — >=1 month of non-bizarre delusions without other psychotic symptoms; function otherwise preserved

Diagnostic workup

Diagnostic criteria

DSM-5-TR: (A) >=2 of delusions, hallucinations, disorganized speech, grossly disorganized/catatonic behavior, negative symptoms — each for a significant portion of 1 month (or less if treated), with at least one being delusions, hallucinations, or disorganized speech; (B) Marked decline in functioning; (C) Continuous signs >=6 months including >=1 month of active symptoms; (D) Schizoaffective and mood disorders with psychosis excluded; (E) Not attributable to substance or medical condition.

Labs

  • CBC, BMP, LFTs, TSH, vitamin B12, syphilis serology, HIV
  • Urine drug screen — essential to exclude substance-induced psychosis
  • Baseline metabolic labs and ECG (QTc) before antipsychotic
  • Pregnancy test in women of reproductive age
  • Consider autoimmune encephalitis workup (anti-NMDA, paraneoplastic panel) for atypical presentations

Imaging

  • MRI brain in first-episode psychosis to exclude structural lesion, demyelination, encephalitis
  • EEG if temporal lobe epilepsy or encephalopathy suspected

Diagnostic algorithm

DisorderActive sx durationTotal durationMood overlap
Brief psychotic1 day - 1 month<1 monthNo
Schizophreniform1-6 months<6 monthsNo
Schizophrenia>=1 month active>=6 monthsNo (or brief)
Schizoaffective>=1 month>=2 wks psychosis w/o moodMajor mood episode concurrent
Mood d/o w/ psychosisVariableLimited to mood episodeAlways
Primary psychotic disorder differentials by duration and mood overlap.

Treatment

First-line

  • Atypical (second-generation) antipsychotic — risperidone, olanzapine, aripiprazole, quetiapine, paliperidone, lurasidone (titrate to lowest effective dose)
  • Long-acting injectable (LAI) antipsychotics for adherence problems — paliperidone palmitate, aripiprazole monohydrate, risperidone microspheres
  • Coordinated specialty care for first-episode psychosis — early intervention improves long-term outcomes
  • Psychosocial: family psychoeducation, cognitive remediation, supported employment, social skills training, assertive community treatment
  • Smoking cessation, metabolic monitoring, cardiovascular risk reduction

Treatment-resistant (>=2 adequate antipsychotic trials)

  • Clozapine — uniquely effective; reduces suicide risk
  • REMS monitoring: weekly ANC for 6 months, then every 2 weeks, then monthly
  • Monitor for agranulocytosis, myocarditis, seizures, ileus, metabolic syndrome, sialorrhea

Acute agitation

  • Verbal de-escalation first; offer PO medication
  • IM olanzapine, haloperidol with benzodiazepine, or aripiprazole IM if needed
  • Avoid combining IM olanzapine + IM benzodiazepine (respiratory depression)

Catatonic features

  • Lorazepam challenge (1-2 mg IV/IM)
  • ECT for benzodiazepine non-response
  • Hold antipsychotics initially if NMS risk

Second-line / adjunct

  • First-generation (typical) antipsychotic — haloperidol, fluphenazine, perphenazine (cost-effective; higher EPS risk)
  • Adjunctive antidepressant for comorbid depression (NOT during active psychosis)
  • Mood stabilizers for aggression or affective lability

Complications

  • Suicide — lifetime risk ~5%; highest early in illness
  • Premature mortality 15-20 years shorter than general population — cardiovascular and metabolic disease
  • Substance use disorders, especially tobacco and cannabis
  • Tardive dyskinesia (especially first-generation), neuroleptic malignant syndrome, metabolic syndrome with atypicals
  • Homelessness, unemployment, social isolation
  • Victimization (more often victims than perpetrators of violence)

PANCE pearls

  • Duration of untreated psychosis predicts outcome — early intervention with coordinated specialty care improves trajectory.
  • Clozapine is the only antipsychotic with demonstrated efficacy in treatment-resistant schizophrenia and reduces suicide risk; underutilized due to monitoring burden.
  • NMS: fever, rigidity, autonomic instability, elevated CK, altered mental status — stop antipsychotic, supportive care, consider dantrolene or bromocriptine.
  • Tardive dyskinesia: late-onset involuntary movements; treat with VMAT2 inhibitors (valbenazine, deutetrabenazine).
  • Monitor metabolic parameters at baseline, 12 weeks, then annually (weight/BMI, BP, fasting glucose, lipids); olanzapine and clozapine have highest metabolic burden.

References

  • APA 2020 — American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia, 3rd ed. (2020)
  • CATIE — Lieberman JA et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. NEJM 2005
  • RAISE — Kane JM et al. Comprehensive Versus Usual Community Care for First-Episode Psychosis. Am J Psychiatry 2016
  • DSM-5-TR — American Psychiatric Association. DSM-5-TR (2022)

Practice Psychiatry/Behavioral questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Related Psychiatry/Behavioral diagnoses

Major Depressive Disorder (MDD)Bipolar I DisorderGeneralized Anxiety Disorder (GAD)Panic DisorderObsessive-Compulsive Disorder (OCD)Post-Traumatic Stress Disorder (PTSD)Borderline Personality Disorder (BPD)Antisocial Personality Disorder (ASPD)Attention-Deficit/Hyperactivity Disorder (ADHD)Autism Spectrum Disorder (ASD)Alcohol Use Disorder (AUD)Opioid Use Disorder (OUD)Stimulant Use DisorderAnorexia Nervosa

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.